https://www.cnbc.com/2024/08/08/novavax-cuts-2024-revenue-forecast-on-lower-covid-vaccine-sales.html
Novavax on Thursday cut its revenue forecast for 2024 as it anticipated lower sales of its COVID-19 vaccine, including the company's updated shot for the fall season targeting the JN.1 variant.
Shares of the company were down 14% in premarket trading.
The vaccine maker now expects $275 million to $375 million in product sales for the year, versus its earlier forecast of between $400 million and $600 million, which also included royalties and other revenue.